extranet

phibro-banner

header1

Phibro Animal Health Corporation partners with MJ Biologics to combat PRRSV

Phibro Animal Health Corporation (PAHC) and MJ Biologics have successfully collaborated to produce a USDA licensed autogenous MJPRRS® vaccine that can help swine producers tackle the complex PRRSV disease problem.

MJPRRS® Viral Antigen Concentrate Vaccine Technology and MJPRRS® Grouping Technology are combined with MVP Technologies' proprietary EMULSIGEN®-D adjuvant to produce the 4th generation MJPRRS® Vaccine. This vaccine contains unique PRRS viral antigens in the presence of MVP Technologies’ adjuvant.

The two companies have scaled-up and optimized the unique MJPRRS® vaccine technology in PAHC’s new virus production facility in Omaha, NE. MJPRRS® vaccines produced by PAHC must pass stringent quality control testing prior to release to assure the targeted levels of antigenic mass. PAHC is able to produce the exclusive autogenous vaccine in various serial sizes up to 100,000 doses.